Cellosaurus logo
expasy logo

Cellosaurus HCV-29 (CVCL_8228)

[Text version]
Cell line name HCV-29
Synonyms HCV.29; HCV 29; HCV29
Accession CVCL_8228
Resource Identification Initiative To cite this cell line use: HCV-29 (RRID:CVCL_8228)
Comments Caution: HCV-29 is said to be a non-malignant bladder epithelial cell line. But due to the fact that it is immortal and contains AKT and BRAF mutations we consider it to be a bladder carcinoma cell line.
Derived from site: In situ; Urinary bladder; UBERON=UBERON_0001255.
Sequence variations
  • Mutation; HGNC; 1097; BRAF; Simple; p.Gly469Val (c.1406G>T); ClinVar=VCV000044803; Zygosity=Heterozygous (PubMed=23401075).
  • Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=24035680).
  • Mutation; HGNC; 12362; TSC1; Simple; p.Gln55Ter (c.163C>T); ClinVar=VCV000048808; Zygosity=Homozygous (PubMed=23401075).
Disease Bladder carcinoma (NCIt: C4912)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_8451 (Hu1734)
Sex of cell Male
Age at sampling Adult
Category Cancer cell line
STR profile Source(s): PubMed=11416159


Run an STR similarity search on this cell line

Williams R.D.
Human urologic cancer cell lines.
Invest. Urol. 17:359-363(1980)

Masters J.R.W., Hepburn P.J., Walker L., Highman W.J., Trejdosiewicz L.K., Povey S., Parkar M., Hill B.T., Riddle P.R., Franks L.M.
Tissue culture model of transitional cell carcinoma: characterization of twenty-two human urothelial cell lines.
Cancer Res. 46:3630-3636(1986)

Debiec-Rychter M., Christensen B., Kieler J., Wang C.Y.
Chromosomal characterization and isoenzyme pattern of non-malignant and malignant human urothelial cell lines.
Anticancer Res. 6:1237-1244(1986)

Christensen B., Hansen C., Kieler J., Schmidt J.
Identity of non-malignant human urothelial cell lines classified as transformation grade I (TGrI) and II (TGrII).
Anticancer Res. 13:2187-2191(1993)

PubMed=8900435; DOI=10.1002/(SICI)1097-0215(19961009)68:2<239::AID-IJC17>3.0.CO;2-5
Klopocki A.G., Krop-Watorek A., Dus D., Ugorski M.
Adhesion of human uroepithelial cells to E-selectin: possible involvement of sialosyl LewisA-ganglioside.
Int. J. Cancer 68:239-244(1996)

PubMed=15846775; DOI=10.1002/gcc.20166
Williams S.V., Adams J., Coulter J., Summersgill B.M., Shipley J.M., Knowles M.A.
Assessment by M-FISH of karyotypic complexity and cytogenetic evolution in bladder cancer in vitro.
Genes Chromosomes Cancer 43:315-328(2005)

PubMed=23401075; DOI=10.1002/path.4176
Guo Y., Chekaluk Y., Zhang J., Du J., Gray N.S., Wu C.-L., Kwiatkowski D.J.
TSC1 involvement in bladder cancer: diverse effects and therapeutic implications.
J. Pathol. 230:17-27(2013)

PubMed=24035680; DOI=10.1016/j.eururo.2013.08.057
Hurst C.D., Platt F.M., Knowles M.A.
Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine.
Eur. Urol. 65:367-369(2014)

PubMed=29732388; DOI=10.3233/BLC-180167
Zuiverloon T.C.M., de Jong F.C., Costello J.C., Theodorescu D.
Systematic review: characteristics and preclinical uses of bladder cancer cell lines.
Bladder Cancer 4:169-183(2018)

PubMed=30193179; DOI=10.1016/j.jmbbm.2018.08.036
Raczkowska J., Prauzner-Bechcicki S.
Discrimination between HCV29 and T24 by controlled proliferation of cells co-cultured on substrates with different elasticity.
J. Mech. Behav. Biomed. Mater. 88:217-222(2018)

Encyclopedic resources Wikidata; Q54882078
Polymorphism and mutation databases Cosmic; 925834
Cosmic; 1286002
Cosmic; 1927313
Cosmic; 2212692
Entry history
Entry creation04-Apr-2012
Last entry update29-Jun-2023
Version number18